Cardiac Biomarkers Market

Size, Share & Trends Analysis Report By Type (Troponin, Creatine kinase - MB (CK-MB), Myoglobin, BNP and NT-proBNP), By Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure), By End Use, By Region, And Segment Forecasts, 2026 - 2033

Cardiac Biomarkers Market Summary

The global cardiac biomarkers market size was estimated at USD 20.81 billion in 2025 and is expected to reach USD 49.31 billion by 2033, growing at a CAGR of 11.5% from 2026 to 2033. The market is driven by the rising prevalence of cardiovascular diseases such as acute coronary syndrome, myocardial infarction, and heart failure, increasing the demand for early and accurate diagnosis.

Advancements in high-sensitivity troponin assays and multi-marker testing have improved clinical decision-making and patient outcomes. In addition, expanding use of point-of-care testing, supportive reimbursement frameworks, and an aging population with higher cardiac risk continue to support market expansion globally.

Cardiovascular diseases are one of the major causes of death globally. According to the World Health Organization (WHO) survey in 2023, it was stated that approximately 17.9 million deaths due to cardiac disorders were reported each year. The prevalence of these conditions continues to rise due to an aging population, obesity, diabetes, and hypertension, leading to an increasing number of individuals at risk of heart attack or heart failure. The growing burden of cardiovascular diseases has created a critical need for early detection, accurate diagnosis, and effective patient monitoring. This is where cardiac biomarkers play a vital role. Biomarkers such as troponin, Creatine Kinase-MB (CK-MB), and myoglobin are essential for detecting myocardial injury and assessing disease severity and therefore help in making treatment decisions.

The rising demand for point-of-care (POC) cardiac testing kits is further expected to propel the growth in the cardiac biomarkers Market. Traditionally, the diagnosis of cardiovascular diseases relied on centralized laboratory testing, which requires specialized instruments and trained personnel. These conventional systems can delay diagnosis and treatment, particularly in acute settings such as emergency department admissions for chest pain or suspected myocardial infarction. Such delays can have serious clinical consequences, as timely identification of cardiac events is critical for initiating interventions and improving patient survival rates. POC cardiac testing kits enable quick diagnostic results for making timely decisions directly at the site of patient care, including emergency rooms, cardiology clinics, and in-home-based settings. Key biomarkers such as troponin, natriuretic peptide (BNP), and creatine kinase-MB (CK-MB) are now measurable at the point of care, allowing clinicians to make faster treatment decisions. For instance, POC cTn tests typically provide results within 10 to 20 minutes.

Emerging biomarkers, including soluble suppression of tumorigenicity-2 (sST2), heart-type fatty acid-binding protein (H-FABP), Galectin-3, and growth differentiation factor-15 (GDF-15), are gaining attention for their potential clinical utility. For instance, a study published by MDPI in August 2025 reported that the biomarkers GDF-15, sST2, suPAR, and H-FABP demonstrated promising potential across a range of cardiovascular diseases.

These novel biomarkers not only reflect different aspects of cardiovascular physiology but also offer the potential to improve early diagnosis and monitoring of treatment response. Advances in technology, including high-sensitivity assays and nanotechnology-based sensors, have further enhanced the ability to detect these biomarkers at very low concentrations, enabling faster and more accurate clinical decision-making. In addition, combining multiple biomarkers into panels allows clinicians to gain a more comprehensive understanding of a patient’s cardiovascular status, moving toward more personalized and precise approaches to care. As research continues and more evidence emerges, these novel cardiac biomarkers are expected to play an important role in improving outcomes for patients with heart disease.

Global Cardiac Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For this report, Grand View Research has segmented the cardiac biomarkers market based on type, application, end use, and region.

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Troponin
• CK-MB
• Myoglobin
• BNP and NT-proBNP
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Acute Coronary Syndrome
• Myocardial Infarction
• Congestive Heart Failure
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Laboratory Testing
• Point of Care Testing
• Regional Outlook (Revenue, USD Million, 2021-2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more